Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa

BACKGROUND: Rilpivirine (TMC278LA) is a promising drug for pre-exposure prophylaxis of HIV-1 because of its sub-nanomolar potency and long-acting formulation; however, increasing transmission of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 with potential cross-resistance to rilpivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Penrose, Kerri J, Brumme, Chanson J, Scoulos-Hanson, Maritsa, Hamanishi, Kristen, Gordon, Kelley, Viana, Raquel V, Wallis, Carole L, Harrigan, P Richard, Mellors, John W, Parikh, Urvi M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890541/
https://www.ncbi.nlm.nih.gov/pubmed/29566538
http://dx.doi.org/10.1177/2040206618762985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890541/
https://www.ncbi.nlm.nih.gov/pubmed/29566538
http://dx.doi.org/10.1177/2040206618762985

Ejemplares similares